Repeated need for tranquillisation ‐ not reported · psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes repeated need for tranquillisation compared with OTHER ANTIPSYCHOTIC: e. OLANZAPINE (very low certainty).
1 finding from 1 review
Specific behaviour ‐ threat or injury to self or others average change score (ABS, high = worse) at 2 hours · psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes specific behaviour ‐ threat or injury to self or others compared with OTHER ANTIPSYCHOTIC: e. OLANZAPINE (very low certainty).
1 finding from 1 review
Global outcome ‐ need for benzodiazepine during 24 hours · psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes global outcome ‐ need for benzodiazepine during 24 hours compared with OTHER ANTIPSYCHOTIC: e. OLANZAPINE (very low certainty).
1 finding from 1 review
Adverse effects: Specific ‐ dystonia during 24 hours · psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: Specific ‐ dystonia during 24 hours compared with OTHER ANTIPSYCHOTIC: e. OLANZAPINE (very low certainty).
1 finding from 1 review
Economic outcome ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tranquillisation or asleep: tranquillised/asleep ‐ by around 30 minutes · acute psychosis
Droperidol showed no clear difference in tranquillisation or asleep: tranquillised/asleep ‐ by around 30… compared with olanzapine (high certainty).
1 finding from 1 review
Global state: use of additional medication ‐ by 60 minutes after initial adequate sedation until ED discharge (various psychotropic drugs) · acute psychosis
Droperidol leads to lower global state: use of additional medication ‐ by 60 minutes after… compared with olanzapine (high certainty).
1 finding from 1 review
Adverse effects ‐ cardiovascular ‐ arrhythmia · acute psychosis
Droperidol showed no clear difference in adverse effects ‐ cardiovascular ‐ arrhythmia compared with olanzapine (moderate certainty).
1 finding from 1 review
Adverse effects ‐ respiratory ‐ airway obstruction · acute psychosis
Droperidol showed no clear difference in adverse effects ‐ respiratory ‐ airway obstruction compared with olanzapine (low certainty).
1 finding from 1 review
Service use: person able to be discharged home · acute psychosis
Droperidol showed no clear difference in service use: person able to be discharged home compared with olanzapine (high certainty).
1 finding from 1 review
Mental state ‐ improvement · acute psychosis
1 finding from 1 review
Economic: direct costs · acute psychosis
1 finding from 1 review
Relapse · patients with schizophrenia
1 finding from 1 review
Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · patients with schizophrenia
1 finding from 1 review
Leaving the study early · patients with schizophrenia
RISPERIDONE DEPOT may leads to higher leaving the study early: Any reason ‐ long term compared with ORAL OLANZAPINE (low certainty).
1 finding from 1 review
Adverse events: General ‐ serious · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in adverse events: General ‐ serious compared with ORAL OLANZAPINE (low certainty).
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
RISPERIDONE DEPOT may leads to higher adverse events: Movement disorder ‐ any extra pyramidal symptoms compared with ORAL OLANZAPINE (low certainty).
1 finding from 1 review
Weight gain · patients with schizophrenia
RISPERIDONE DEPOT may leads to lower adverse events: Specific ‐ weight increase compared with ORAL OLANZAPINE (low certainty).
1 finding from 1 review
Adverse effects: Specific and serious adverse effect ‐ by 24 hours Central nervous system ‐ excessive sedation · people with psychosis‐induced aggression
HALOPERIDOL + PROMETHAZINE showed no clear difference in adverse effects: Specific and serious adverse effects by 24 hours… compared with ANTIPSYCHOTIC ‐ OLANZAPINE (low certainty).
1 finding from 1 review
Adverse effect: Specific ‐ Death · people with psychosis‐induced aggression
1 finding from 1 review